14 completed, 9 recruiting, 6 terminated, 3 active not recruiting. 16 Phase 2, 12 Phase 1, 8 Phase 3.
Follow Post-essential Thrombocythemia Myelofibrosis: new trials by email Literature Review of Post-essential Thrombocythemia Myelofibrosis trials Research Report on Post-essential Thrombocythemia Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms PRT12396 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Recruiting | Prelude Therapeutics Incorporated | 100 | 2026-04-29 | 2026-10-01 |
| Research Platform Myelofibrosis and Anemia Primary Myelofibrosis, Secondary Myelofibrosis | Recruiting | iOMEDICO AG | 200 | 2026-02-19 | 2026-06-05 | |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2024-05-23 | 2026-04-02 |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Talazoparib, pacritinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 | Recruiting | Fox Chase Cancer Center | 24 | 2024-04-05 | 2024-05-03 |
| Real World Evidence of Fedratinib Effectiveness in MF Fedratinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 93 | 2024-01-29 | 2024-02-08 | |
| A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis Fedratinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Recruiting | Bristol-Myers Squibb | 137 | 2023-06-13 | 2024-11-06 | |
| Asian Myeloproliferative Neoplasm (MPN) Registry Myeloproliferative Neoplasm, Polycythemia Vera | Recruiting | The University of Hong Kong | 1000 | 2023-05-01 | 2023-05-31 | |
| Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis NS-018, Best Available Therapy - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Terminated | NS Pharma, Inc. | 7 | 2023-01-31 | 2025-05-23 |
| Study of Canakinumab in Patients With Myelofibrosis Canakinumab - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Active not recruiting | John Mascarenhas | 14 | 2022-08-02 | 2026-05-07 |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia DISC-0974 - Myelofibrosis; Anemia, Anemia | Phase 1 / Phase 2 | Recruiting | Disc Medicine, Inc | 150 | 2022-06-06 | 2026-10-22 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Pelabresib, Ruxolitinib, Placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 430 | 2021-04-09 | 2026-07-17 |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia LNK01002 - Acute Myeloid Leukemia, Primary Myelofibrosis | Phase 1 | Withdrawn | Lynk Pharmaceuticals Co., Ltd | 2021-04-08 | 2023-06-18 | |
| INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders INCB000928, ruxolitinib - Anemia, Post-essential Thrombocythemia Myelofibrosis | Phase 1 / Phase 2 | Completed | Incyte Corporation | 84 | 2021-03-19 | 2026-10-01 |
| Study of Select Combinations in Adults With Myelofibrosis MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2020-11-30 | 2021-03-04 | |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) Momelotinib, Placebo to match danazol, Danazol - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Completed | Sierra Oncology LLC - a GSK company | 195 | 2020-02-07 | 2023-11-01 |
| Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors Selinexor - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Terminated | University of Utah | 17 | 2019-05-10 | 2026-10-26 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Terminated | Celgene | 38 | 2019-03-27 | 2024-12-12 |
Showing 20 of 36. Sign in to see all of them.
Primary Myelofibrosis (35) · Polycythemia Vera (13) · Myeloproliferative Disorders (11) · Anemia (9) · Thrombocythemia, Essential (9) · Hematologic Diseases (6) · Bone Marrow Diseases (5) · Splenomegaly (4) · Thrombocytopenia (3) · Fibrosis (2) · Hemorrhagic Disorders (2) · Blast Crisis (1) · Blood Platelet Disorders (1) · Bone Marrow Neoplasms (1) · Disease Progression (1)
Hemic and Lymphatic Diseases (36) · Bone Marrow Diseases (30) · Hematologic Diseases (30) · Myeloproliferative Disorders (24) · Neoplasms (13) · Neoplasms by Site (13) · Bone Marrow Neoplasms (12) · Hematologic Neoplasms (12) · Blood Platelet Disorders (10) · Blood Coagulation Disorders (9) · Thrombocytosis (9) · Hemorrhagic Disorders (8) · Pathological Conditions, Signs and Symptoms (7) · Hypertrophy (4) · Pathologic Processes (4)
ruxolitinib (10) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (7) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (5) · fedratinib (4) · Danazol (2) · selinexor (2) · 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- (1) · Adrenal Cortex Hormones (1) · Decitabine (1) · Hydroxyurea (1) · NIS-793 (1) · bomedemstat (1) · canakinumab (1) · pembrolizumab (1) · revumenib (1)
Sierra Oncology LLC - a GSK company (6) · John Mascarenhas (5) · Novartis Pharmaceuticals (4) · CTI BioPharma (2) · Incyte Corporation (2) · NS Pharma, Inc. (2) · Bristol-Myers Squibb (1) · Celgene (1) · Disc Medicine, Inc (1) · Fox Chase Cancer Center (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hoffmann-La Roche (1) · Lynk Pharmaceuticals Co., Ltd (1) · MPN Research Foundation (1) · Merck Sharp & Dohme LLC (1)
United States (29) · Canada (13) · Australia (12) · Germany (11) · France (10) · Italy (10) · United Kingdom (10) · Belgium (6) · Czechia (6) · Hungary (6) · South Korea (6) · Spain (6) · Israel (5) · Netherlands (5) · Poland (5)
John Mascarenhas, MD (5) · Ayalew Tefferi, MD (2) · Simran Singh (2) · Srdan Verstovsek, M.D., Ph.D. (2) · Abdulraheem Yacoub, MD (1) · Amanda McBride, MD (1) · Andrew Roberts, MD (1) · Animesh Pardanani, MD (1) · Anthony M Hunter, MD (1) · Beth Ziemba (1)
PMID 42316774, PMID 33275766, PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 42452788, PMID 27479177, PMID 27634203, PMID 29515114, PMID 30086777, PMID 33232476, PMID 34551507, PMID 34581778, PMID 35950489, PMID 36709073, PMID 37165840, PMID 37517413, PMID 37792065, PMID 38501751, PMID 38837732, PMID 38838026, PMID 39400386, PMID 40065169, PMID 40619737, PMID 40643151, PMID 40691344
2023 (3), P01CA108671 (3), 2015 (1), 2018 (1), 2019 (1)